2nd Circ. Affirms Dismissal Of FCA Suit Against Amgen
By John Kennedy (December 18, 2017, 7:33 PM EST) -- A whistleblower claiming Amgen Inc. cost the government billions by falsely advertising quality of life benefits for its anemia biologic Epogen failed to actually identify anything that tricked the government into reimbursing claims for the drug, the Second Circuit said Monday, affirming a lower court's dismissal of the False Claims Act suit.
Even adopting, for argument's sake, relator Dr. Daniel Coyne's interpretation of the Normal Hematocrit Trial — an unfinished Amgen trial that ran from 1993-96 — Coyne couldn't show that any alleged Amgen misrepresentations affected reimbursement decisions made by the Centers for Medicare & Medicaid Services, the three-judge panel said....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!